Physician profile
Christopher J Pole
NPI 1285883231
$128,529.97
in general payments reported to CMS, 2019-2025
23 companies · $9,651 in 2025
The $9,651 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $209 · 2021: $358 · 2022: $74K · 2023: $33K · 2024: $11K · 2025: $9,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $49K · Food and Beverage: $3,769 · Travel and Lodging: $744 · Honoraria: $25.59 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,064.96 |
| Food and Beverage | $3,768.87 |
| Travel and Lodging | $744.01 |
| Honoraria | $25.59 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microsurgical Technology, INC. | $96,405.86 | 2022-2024 | |
| Rxsight INC | $27,890.90 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Glaukos Corporation | $1,271.35 | 2019-2025 | Idosetr, Istent Infinite, Idose |
| Alcon Vision LLC | $1,133.15 | 2019-2025 | Clareon, Rocklatan, Unity |
| The Cameron-Ehlen Group, INC. | $495.37 | 2021-2022 | |
| Allergan, INC. | $202.70 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $146.67 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $132.68 | 2019-2024 | Tecnis Iol |
| Ocular Therapeutix, INC. | $124.71 | 2022 | |
| Horizon Therapeutics Plc | $115.80 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $103.07 | 2025 | |
| Sun Pharmaceutical Industries INC. | $97.54 | 2019-2024 | |
| Harrow Eye, LLC | $91.94 | 2024-2025 | Iheezo |
| Beaver-Visitec International, INC. | $70.95 | 2025 | |
| Bausch & Lomb Americas INC. | $66.57 | 2024-2025 | Envista Envy Iol, Miebo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $54.08 | 2020-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.14 | 2019 | |
| Eyevance Pharmaceuticals LLC | $19.44 | 2023 | Flarex |
| Mallinckrodt Enterprises LLC | $17.01 | 2019 | |
| Amgen INC. | $16.74 | 2025 | Tepezza |
| Abbvie INC. | $13.20 | 2023 | |
| Novartis Pharmaceuticals Corporation | $12.10 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.